Drug – bio-affecting and body treating compositions – Enzyme or coenzyme containing – Hydrolases
Patent
1995-04-26
1997-03-25
Jacobson, Dian C.
Drug, bio-affecting and body treating compositions
Enzyme or coenzyme containing
Hydrolases
435212, 435226, 4353201, 4352523, 435369, 435359, 536 232, 424 9463, A61K 3849, C12N 950, C12N 964, C12N 1555
Patent
active
056141904
ABSTRACT:
Tissue plasminogen activator (t-PA) zymogens and variants are prepared, including a fibrinolytically active variant of t-PA that has an amino acid alteration at a site within the protease domain of t-PA as compared with the corresponding wild-type t-PA, which alteration renders the variant zymogenic in the presence of plasmin-degraded fibrinogen, and/or fibrin (or plasma clot) specific, as compared to the corresponding wild-type t-PA. DNA sequences can be prepared that encode the zymogens and variants, as well as expression vectors incorporating the DNA sequences, and host cells transformed with the expression vectors. The zymogens and variants may be used in a pharmaceutical preparation to treat a vascular disease or condition or to prevent fibrin deposition or adhesion formation or reformation in mammals.
REFERENCES:
patent: 4752603 (1988-06-01), Collen et al.
patent: 4753879 (1988-06-01), Rosa
patent: 4766075 (1988-08-01), Goeddel et al.
patent: 5108901 (1992-04-01), Anderson et al.
patent: 5246850 (1993-09-01), Bennett et al.
patent: 5258180 (1993-11-01), Gill et al.
patent: 5262170 (1993-11-01), Anderson et al.
patent: 5270198 (1993-12-01), Anderson et al.
patent: 5304482 (1994-04-01), Sambrook et al.
patent: 5344773 (1994-09-01), Wei et al.
patent: 5405771 (1995-04-01), Anderson et al.
patent: 5486602 (1996-06-01), Sambrook et al.
Pharmacia Fine Chemicals Catalogue 84 (1 and 6) (1984).
Webster's II New Riverside Univeristy Dictionary, ex:The Riverside Publishing Company p. 126 (1984).
Browne et al., "A Tissue-Type Plasminogen Activator Mutant with Prolonged Clearance In Vivo" Journal of Biological Chemistry 263 (4):1599-1602 (1988).
Gardell et al., "Isolation, Characterization, and cDNA Cloning of a Vampire Bat Salivary Plasminogen Activator" Journal of Biological Chemistry 264(30):17947-17952 (1989).
Harris, "Second-Generation Plasminogen Activators" Protein Engineering 1(6):449-458 (1987).
Huber and Bode, "Structural Basis of the Activation and Action of Trypsin" Accounts of Chemical Research 11:114-122 (1978).
Kassell et al., "Zymogens of Proteolytic Enzymes" Science 180:1022-1027 (1973).
Kaufman et al., "Expression and Amplification of DNA Introduced into Mammalian Cells" Gene Amplification, Cold Spring Harbor Laboratory pp. 245-250 (1982).
Madison et al., "Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor 1" Proc. Natl. Acad. Sci. USA 87:3530-33 (1990).
Madison et al., "Serpin-Resistant Mutants of Human Tissue-Type Plasminogen Activator" Nature 339:721-724 (1989).
Ny et al., "Cloning and Characterization of a cDNA for Rat Tissue-Type Plasminogen Activator" DNA 7(10):671-677 (1988).
Pannekoek et al., "Mutants of human tissue-type plasminogen activator (t-PA): structural aspects and functional properties" Fibrinolysis 2:123-132 (1988).
Pennica et al., "Cloning and Expression of Human Tissue-type Plasminogen Activator cDNA in E. coli," Nature 301:214-221 (1983).
Petersen et al., "The effect of polymerised fibrin on the catalytic activities of one-chain tissue-type plasminogen activator as revealed by an analogue resistant to plasmin cleavage" Biochimeca Et Biophysica Acta 952:245-254 (1988).
Rickles et al., "Molecular Cloning of Complementary DNA to Mouse Tissue Plasminogen Activator mRNA and Its Expression During F9 Teratocarcinoma Cell Differentiation" Journal of Biological Chemistry 263(3):1563-1569 (1988).
Rijken and Collen, "Purification and Characterization of the Plasminogen Activator Secreted by Human Melanoma Cells in Culture," Journal of Biological Chemistry 256(13):7035-7041 (1981).
Rijken et al., "Fibrinolytic Properties of One-chain and Two-chain Human Extrinsic (Tissue-type) Plasminogen Activator" Journal of Biological Chemistry 257:2920-2925 (1982).
Ringe, D., "The sheep in Wolf's clothing" Nature 339:658-659 (1989).
Ross et al., "Plasminogen Activators" Annual Reports in Medicinal Chemistry, Chapter 12, 23:111-120 (1988).
Tate et al., "Functional role of proteolytic cleavage at arginine-275 of human tissue plasminogen activator as assessed by site-directed mutagenesis" Biochemistry 26:338-343 (1987).
van Zonneveld et al. Thrombos. Haemostas. 54(1):4-(1985).
Montz et al., "The ability of recombinant tissue plasminogen activator to inhibit post-radical pelvic surgery adhesions in the dog model" Am. J. Obstet. Gynecol. 165 (5 Pt. 1):1539-1542 (1991).
Pados and Devroey, "Adhesions" Curr. Opin. Obstet. Gynecol. 4(3):412-418 (1992).
Vipond et al., "Experimental adhesion prophylaxis with recombinant tissue plasminogen activator" Ann. R. Coll. Surg. Engl. 76(6):412-415 (1994).
Wiseman et al., "Fibrinolytic drugs prevent pericardial adhesions in the rabbit" J. Surg. Res. 53:362-368 (1992).
Anderson Stephen
Bennett William F.
Botstein David
Higgins Deborah L.
Paoni Nicholas F.
Dreger Ginger R.
Genentech Inc.
Jacobson Dian C.
LandOfFree
Tissue plasminogen activator having zymogenic or fibrin specific does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tissue plasminogen activator having zymogenic or fibrin specific, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tissue plasminogen activator having zymogenic or fibrin specific will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2201073